[Alitretinoin: a new treatment option for chronic refractory hand eczema].
About 10% of Germans have chronic hand eczema (CHE). Until recently only off-label use agents existed for the treatment of severe CHE cases refractory to topical steroids. In addition, data from controlled clinical trials confirming the efficacy of known treatment strategies was inadequate. With the availability of alitretinoin, 9-cis retinoic acid, this situation may change. In two large clinical trials alitretinoin showed high response rates and a favorable safety profile in the treatment of severe and refractory CHE. Alitretinoin has an anti-inflammatory and immunomodulatory mechanism of action. Acting as a panagonist it binds to retinoic acid receptors A (RAR) and X (RXR). It directly affects cytokine production in keratinocytes and down-regulates leukocyte activity. When used for CHE with detailed patient counseling and appropriate laboratory monitoring, alitretinoin is a promising new option for systemic treatment.
Molin
S
S
Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität, Frauenlobstrasse 9-11, 80337, München, Deutschland.
Ruzicka
T
T
D000077556:Alitretinoin; D000890:Anti-Infective Agents / Q000008:administration & dosage; D002908:Chronic Disease; D002986:Clinical Trials as Topic / Q000639:trends*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004485:Eczema / Q000188:drug therapy*; D006229:Hand Dermatoses / Q000188:drug therapy*; D006801:Humans; D012008:Recurrence; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D003879:Dermatologic Agents; D000077556:Alitretinoin; D014212:Tretinoin